A heavily studied mobile medical app intended to support treatment of opioid use disorder (OUD) is among the first 510(k)-route products to gain entry into US FDA's Breakthrough Devices Program, providing some insight into the types of products that might be considered breakthroughs even though they are seeking a "substantial equivalence" claim to something already on the market.
Pear Therapeutics announced Expedited Access Pathway designation earlier this month for its reSET-O Prescription Digital Therapeutic for OUD. FDA has recently started to refer to the 2015-launch EAP program as the Breakthrough Devices Program to align with a provision of the 21st Century Cures Act that updates the program. The agency issued a draft guidance Oct. 24 on the updated program, which offers an expedited development route for devices that may address an unmet need for life-threatening or irreversibly debilitating diseases or conditions
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?